![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PITRM1 |
Gene summary for PITRM1 |
![]() |
Gene information | Species | Human | Gene symbol | PITRM1 | Gene ID | 10531 |
Gene name | pitrilysin metallopeptidase 1 | |
Gene Alias | MP1 | |
Cytomap | 10p15.2 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q5JRX3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10531 | PITRM1 | LZE4T | Human | Esophagus | ESCC | 5.45e-06 | 1.31e-01 | 0.0811 |
10531 | PITRM1 | LZE8T | Human | Esophagus | ESCC | 2.48e-08 | 1.84e-01 | 0.067 |
10531 | PITRM1 | LZE22T | Human | Esophagus | ESCC | 2.53e-03 | 2.44e-01 | 0.068 |
10531 | PITRM1 | LZE24T | Human | Esophagus | ESCC | 2.24e-15 | 3.87e-01 | 0.0596 |
10531 | PITRM1 | LZE6T | Human | Esophagus | ESCC | 8.07e-05 | 2.04e-01 | 0.0845 |
10531 | PITRM1 | P1T-E | Human | Esophagus | ESCC | 2.24e-03 | 3.72e-01 | 0.0875 |
10531 | PITRM1 | P2T-E | Human | Esophagus | ESCC | 1.96e-13 | 1.84e-01 | 0.1177 |
10531 | PITRM1 | P4T-E | Human | Esophagus | ESCC | 1.13e-16 | 2.48e-01 | 0.1323 |
10531 | PITRM1 | P5T-E | Human | Esophagus | ESCC | 3.89e-10 | 1.54e-01 | 0.1327 |
10531 | PITRM1 | P8T-E | Human | Esophagus | ESCC | 4.41e-11 | 2.21e-01 | 0.0889 |
10531 | PITRM1 | P9T-E | Human | Esophagus | ESCC | 1.17e-06 | 6.40e-02 | 0.1131 |
10531 | PITRM1 | P10T-E | Human | Esophagus | ESCC | 4.05e-12 | 1.05e-01 | 0.116 |
10531 | PITRM1 | P11T-E | Human | Esophagus | ESCC | 1.13e-06 | 2.84e-01 | 0.1426 |
10531 | PITRM1 | P12T-E | Human | Esophagus | ESCC | 5.68e-14 | 2.81e-01 | 0.1122 |
10531 | PITRM1 | P15T-E | Human | Esophagus | ESCC | 2.48e-18 | 1.71e-01 | 0.1149 |
10531 | PITRM1 | P16T-E | Human | Esophagus | ESCC | 3.27e-07 | 1.29e-01 | 0.1153 |
10531 | PITRM1 | P17T-E | Human | Esophagus | ESCC | 4.74e-10 | 3.37e-01 | 0.1278 |
10531 | PITRM1 | P19T-E | Human | Esophagus | ESCC | 3.35e-07 | 3.13e-01 | 0.1662 |
10531 | PITRM1 | P20T-E | Human | Esophagus | ESCC | 1.28e-09 | 1.64e-01 | 0.1124 |
10531 | PITRM1 | P21T-E | Human | Esophagus | ESCC | 2.76e-35 | 6.45e-01 | 0.1617 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007265518 | Oral cavity | OSCC | establishment of protein localization to mitochondrion | 88/7305 | 120/18723 | 2.10e-14 | 1.19e-12 | 88 |
GO:000662618 | Oral cavity | OSCC | protein targeting to mitochondrion | 72/7305 | 100/18723 | 2.10e-11 | 7.18e-10 | 72 |
GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
GO:00164856 | Oral cavity | OSCC | protein processing | 121/7305 | 225/18723 | 4.56e-06 | 5.23e-05 | 121 |
GO:007259419 | Oral cavity | LP | establishment of protein localization to organelle | 205/4623 | 422/18723 | 6.76e-27 | 3.85e-24 | 205 |
GO:0006605110 | Oral cavity | LP | protein targeting | 156/4623 | 314/18723 | 5.43e-22 | 1.62e-19 | 156 |
GO:000683919 | Oral cavity | LP | mitochondrial transport | 119/4623 | 254/18723 | 1.06e-14 | 1.33e-12 | 119 |
GO:007058519 | Oral cavity | LP | protein localization to mitochondrion | 70/4623 | 125/18723 | 6.73e-14 | 7.02e-12 | 70 |
GO:007265519 | Oral cavity | LP | establishment of protein localization to mitochondrion | 68/4623 | 120/18723 | 6.98e-14 | 7.16e-12 | 68 |
GO:000662619 | Oral cavity | LP | protein targeting to mitochondrion | 58/4623 | 100/18723 | 1.23e-12 | 1.00e-10 | 58 |
GO:005160416 | Oral cavity | LP | protein maturation | 122/4623 | 294/18723 | 1.37e-10 | 7.72e-09 | 122 |
GO:001648513 | Oral cavity | LP | protein processing | 83/4623 | 225/18723 | 2.87e-05 | 4.52e-04 | 83 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PITRM1 | SNV | Missense_Mutation | c.2801N>T | p.Gln934Leu | p.Q934L | Q5JRX3 | protein_coding | deleterious(0.03) | benign(0.21) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR | |
PITRM1 | SNV | Missense_Mutation | c.2180N>T | p.Ala727Val | p.A727V | Q5JRX3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
PITRM1 | SNV | Missense_Mutation | c.2747N>G | p.Asn916Ser | p.N916S | Q5JRX3 | protein_coding | tolerated(0.77) | benign(0.001) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PITRM1 | SNV | Missense_Mutation | c.795C>G | p.Phe265Leu | p.F265L | Q5JRX3 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PITRM1 | SNV | Missense_Mutation | novel | c.769N>A | p.His257Asn | p.H257N | Q5JRX3 | protein_coding | deleterious(0) | possibly_damaging(0.893) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
PITRM1 | SNV | Missense_Mutation | c.1987N>C | p.Glu663Gln | p.E663Q | Q5JRX3 | protein_coding | deleterious(0) | possibly_damaging(0.869) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PITRM1 | SNV | Missense_Mutation | rs534536142 | c.2896N>A | p.Ala966Thr | p.A966T | Q5JRX3 | protein_coding | deleterious(0.03) | possibly_damaging(0.493) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
PITRM1 | insertion | Nonsense_Mutation | novel | c.2118_2119insTATACGTAATTTTTCAAACAGGTGTTCAGTGAATGCG | p.Thr707TyrfsTer3 | p.T707Yfs*3 | Q5JRX3 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PITRM1 | insertion | Nonsense_Mutation | novel | c.1800_1801insAAATATCAGATTTAGAAATGATCACAAAGGATATATCTGAAG | p.Ala600_Phe601insLysTyrGlnIleTerLysTerSerGlnArgIleTyrLeuLys | p.A600_F601insKYQI*K*SQRIYLK | Q5JRX3 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PITRM1 | deletion | Frame_Shift_Del | novel | c.2875delT | p.Ser959LeufsTer6 | p.S959Lfs*6 | Q5JRX3 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |